Comparative Pharmacology
Head-to-head clinical analysis: ORASONE versus TRIACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORASONE versus TRIACORT.
ORASONE vs TRIACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Orasone (prednisone) is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory cytokines, immune response, and adrenal function.
Adrenocorticosteroid; binds to glucocorticoid receptor, modulating gene expression to produce anti-inflammatory, immunosuppressive, and metabolic effects.
Adults: 5-60 mg orally once daily or divided twice daily; typical starting dose 5-40 mg/day. Route: oral. Frequency: once daily or every 12 hours.
10-20 mg orally once daily
None Documented
None Documented
Terminal half-life of 3-4 hours for prednisolone (active metabolite of ORASONE); clinically, duration of HPA-axis suppression is more relevant (12-36 hours) with longer effects at higher doses.
Clinical Note
moderateDiflorasone + Gatifloxacin
"The risk or severity of adverse effects can be increased when Diflorasone is combined with Gatifloxacin."
Clinical Note
moderateDiflorasone + Rosoxacin
"The risk or severity of adverse effects can be increased when Diflorasone is combined with Rosoxacin."
Clinical Note
moderateDiflorasone + Levofloxacin
"The risk or severity of adverse effects can be increased when Diflorasone is combined with Levofloxacin."
Clinical Note
moderateDiflorasone + Trovafloxacin
2-3 h. The terminal elimination half-life is short, requiring thrice-daily dosing for sustained effect. Context: In patients with hepatic impairment, half-life may be prolonged up to 4-5 h.
Primarily renal: ~80% as 17-keto metabolites and unchanged drug; biliary/fecal excretion accounts for <10%.
Primarily hepatic metabolism (>90%) with renal excretion of inactive metabolites (approximately 80% in urine, 20% in feces). Less than 5% of the parent drug is excreted unchanged in urine.
Category C
Category C
Corticosteroid
Corticosteroid
"The risk or severity of adverse effects can be increased when Diflorasone is combined with Trovafloxacin."